EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors
WEST PALM BEACH, FL. June 16, 2020 – EXUMA Biotech Corporation, a clinical-stage biotechnology company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, is pleased to announce that H. Michael Shepard, Ph.D., an acting advisor to the company’s HER2 program, has been appointed to the Scientific Advisory Board. Additionally, Steven […]
Let’s Get the CAR-T Started
“Cancer is effectively a unicellular perspective on immortality, which has broken the social contract,” he says. “So when we look at the ability of cellular therapies to assist in that immunologic process of being able to treat patients and help them from the perspective of aging, I think that cancer is something which is one […]
Chairman & CEO Greg Frost on the Empowered Patient podcast with Karen Jagoda
Dr. Gregory Frost, Chairman & CEO of EXUMA Biotechnology, shares his insights into the tremendous progress made in developing autologous CAR-T therapies, as well as the challenges that remain for cell therapies surrounding safety and accessibility with Karen Jagoda on the Empowered Patient Podcast. EXUMA’s own “rPOC” (meaning “rapid point of care”) platform has the […]
F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
WEST PALM BEACH, FL. March 12, 2020 – EXUMA Biotech Corp. (formerly F1 Oncology), a clinical-stage biotechnology company discovering and developing CAR-T therapies for solid and liquid tumors, today announced a $19M Series B round of financing that includes new investments by MSD Partners and F1 BioVentures, as well as conversion of notes held by […]
EXUMA Biotechnology Expands Leadership Team with Appointment of Chief Medical Officer and Chief Financial Officer
SHANGHAI and WEST PALM BEACH, Fla., June 18, 2019 — EXUMA Biotechnology, a clinical-stage biotechnology company discovering and developing CAR-T products for solid tumors and affiliate of F1 Oncology, Inc., announced today the expansion of its leadership team with the appointment of Wendy Li, M.D. as Chief Medical Officer and James Samuels as Chief Financial […]
Shanghai Perhum Therapeutics Announces Preliminary Results Of Two First-in-Human Solid Tumor CAR-T Products
MAINZ, Germany, May 21, 2019 — EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics announced today interim results of two first-in-human solid tumor CAR-T products in subjects with recurrent or refractory stage IV metastatic renal cell carcinoma (mRCC). The data, presented at the Association for Cancer Immunotherapy (CIMT) 2019 Annual Meeting, continues to support the feasibility, […]
F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies
ATLANTA, March 31, 2019 — F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, will present four abstracts at the American Association of Cancer Research (AACR) 2019 Annual Meeting in Atlanta from March 29-April 3, 2019 that support novel technologies to treat solid tumor malignancies. F1 Oncology is developing these […]
F1 Oncology’s International Affiliate, Exuma Biotechnology, Announces Acquisition of Strategic Car-T Assets
SHANGHAI and WEST PALM BEACH, Fla., November 13, 2018 — F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, today announced that its international affiliate, EXUMA Biotechnology Hong Kong, has formed Shanghai EXUMA Biotechnology Co., Ltd., a wholly foreign-owned enterprise (WFOE), to acquire all rights to novel chimeric antigen […]
F1 Oncology Announces Development Milestone and $10M Equity Investment
Shanghai, PRC and West Palm Beach, FL – January 7th, 2018 – F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, today announced receipt of a $10 million equity investment from its current investors upon ethics committee approval of a novel precision medicine-directed […]
F1 Oncology’s International Affiliates and Sinobioway Sunterra Biotechnology Announce New Development, Manufacturing, and Supply Agreements to Support cGMP Lentivirus Supply
SHENZHEN, SHANGHAI, HONG KONG AND GRAND CAYMAN–January 7th, 2018–Shanghai Sinobioway Sunterra Biotechnology (SSSB) and F1 Oncology today announced the signing of new development, manufacturing, and supply agreements with plans to complete a new cGMP manufacturing facility in Shenzhen in support of large scale lentivirus contract manufacturing. The new facility, Shenzhen […]
